A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia.
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2012
At a glance
- Drugs T 62 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- 07 Jun 2012 Company (Pfizer) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Planned number of patients changed from 130 to 19 as reported by ClinicalTrials.gov.
- 07 Jul 2009 Planned end date changed from 1 Dec 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.